Glenmark Pharma Share: How Will the ₹19,000 Cr AbbVie Deal Benefit the Company?

Synopsis: The share of this pharmaceutical company remains supported by strong growth guidance, improving global business momentum, and a Rs 19,000 crore AbbVie deal that could unlock long-term value from its innovation pipeline.

The article outlines the significance of the deal and the outlook of the company, which specializes in developing branded generics, specialty drugs, and OTC products, with a primary focus on the therapeutic areas of dermatology, respiratory, and oncology.

With a market capitalization of Rs 60,870 crore, Glenmark Pharmaceuticals Ltd’s share closed at Rs 2,156 per share, up 0.95 from its previous day’s close. The share of this company gave a return of 30 percent over the last year.

Brokerage View

Investec maintains a Buy rating on Glenmark with a revised target price of Rs 2,750, implying around 27.5 percent upside from closing , supported by strong earnings visibility through FY30.

Growth Guidance Supports Long-Term Earnings Visibility: The company has guided for 13 to 15 percent sales growth and around 100 basis points of margin expansion by FY30. Management expects the branded pharmaceutical business and a higher contribution from innovation-led products to be the key drivers of growth, supporting stronger profitability and long-term earnings visibility.

India Business Expected To Deliver Above 15 Percent Growth: The domestic business remains a major growth pillar, with management expecting growth of over 15 percent. This outlook is supported by new product launches, expansion of the GLP-1 portfolio, increasing focus on oncology, and the addition of more medical representatives to strengthen market penetration.

US Recovery and RoW Growth Provide Additional Tailwinds: The US business is approaching an inflection point, driven by growth in respiratory and injectable products, Monroe integration benefits, and First-to-File (FTF) launch opportunities. At the same time, the Rest of World (RoW) business continues to deliver steady and sustainable growth, providing additional support to overall revenues.

IGI Innovation Platform Adds Future Upside Potential: The company’s innovation arm, IGI, offers long-term growth optionality following the AbbVie deal. Management plans to file at least one Investigational New Drug (IND) application every year from FY27 and remains open to pursuing additional strategic transactions, which could create new revenue streams and unlock shareholder value over time.

Key highlights of the deal: 

AbbVie Deal Validates Innovation Platform: Glenmark’s innovation arm, IGI, signed a landmark USD 1.925 billion (around Rs 19,000 crore) licensing deal with AbbVie for ISB 2001. The agreement validates the company’s research capabilities and highlights the potential of its proprietary BEAT platform in oncology and autoimmune diseases.

Creates A New Long-Term Growth Engine: Beyond the USD 700 million upfront payment, the deal offers milestone-based earnings and future royalty opportunities. This could diversify Glenmark’s revenue mix and establish innovation as a meaningful contributor alongside its core branded and generic pharmaceutical businesses.

Potential for More Strategic Partnerships: The success of the AbbVie transaction enhances the credibility of Glenmark’s innovation pipeline globally. With management targeting continued pipeline development, the company could attract additional licensing deals and partnerships, creating long-term value and supporting its next phase of growth.

Conclusion: The AbbVie partnership marks a significant milestone in Glenmark’s transition from a traditional generics-focused company to an innovation-driven pharmaceutical player. Coupled with strong growth guidance, improving domestic and US business prospects, and a growing innovation pipeline, the deal could strengthen long-term earnings visibility and create additional value creation opportunities over the coming years.

About the Company

Glenmark Pharmaceuticals is a global, research-led pharmaceutical company headquartered in Mumbai, India. Founded in 1977, it specializes in developing branded generics, specialty drugs, and OTC products, with a primary focus on the therapeutic areas of dermatology, respiratory, and oncology

Financial Highlight: The revenue from operations grew by 16 percent to Rs 3,771 crore in Q4 FY26 from Rs 3,256 crore in Q4 FY25, and EBIDT grew by 36 percent to Rs 763 crore in Q4 FY26 from Rs 561 crore in Q4 FY25. This was accompanied by a net profit growth of 52 percent to Rs 301 crore in Q4 FY26 from Rs 4.38 crore in Q4 FY25, resulting in an EPS growth of 6575 percent to Rs 10.68 per share in Q4 FY26 from Rs 0.16 per share in Q4 FY25.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Glenmark Pharma Share: How Will the ₹19,000 Cr AbbVie Deal Benefit the Company? appeared first on Trade Brains.